1 week Ago By ABMN Staff
Needham & Company LLC reaffirmed their buy rating on shares of Neumora Therapeutics ( NASDAQ:NMRA – Free Report ) in a research report released on Thursday morning, Benzinga reports. They currently have a $23.00 target price on the stock.
Other analysts also recently issued reports about the company. JPMorgan Chase & Co. downgraded Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $18.
00 to $15.00 in a research report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and set a $30.
00 price target on shares of Neumora Therapeutics in a report on Monday, December 16th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 price target on shares of Neumora Therapeutics in a research note on Friday, November 22nd.
Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Neumora Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $18.40.
Read Our Latest Analysis on NMRA Neumora Therapeutics Price Performance Neumora Therapeutics ( NASDAQ:NMRA – Get Free Report ) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.
39) by ($0.06). During the same quarter last year, the business earned ($1.
14) earnings per share. Research analysts expect that Neumora Therapeutics will post -1.61 EPS for the current year.
Insider Activity In other news, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $17.
03, for a total transaction of $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares of the company’s stock, valued at $342,303.
The trade was a 41.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link .
Also, insider Robert A. Lenz sold 5,563 shares of the stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $15.
01, for a total value of $83,500.63. Following the completion of the sale, the insider now directly owns 322,966 shares of the company’s stock, valued at approximately $4,847,719.
66. This trade represents a 1.69 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . 26.40% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Neumora Therapeutics Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its holdings in Neumora Therapeutics by 2.
6% during the third quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company’s stock worth $851,000 after acquiring an additional 1,629 shares during the period.
Amalgamated Bank boosted its stake in Neumora Therapeutics by 472.8% in the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock valued at $29,000 after acquiring an additional 2,402 shares during the last quarter.
Handelsbanken Fonder AB increased its stake in shares of Neumora Therapeutics by 35.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company’s stock worth $351,000 after purchasing an additional 6,900 shares during the last quarter.
Quarry LP bought a new stake in shares of Neumora Therapeutics in the second quarter valued at $98,000. Finally, Intech Investment Management LLC purchased a new position in shares of Neumora Therapeutics during the 3rd quarter valued at $175,000. 47.
65% of the stock is owned by institutional investors. About Neumora Therapeutics ( Get Free Report ) Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
See Also Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
